Co-Authors
This is a "connection" page, showing publications co-authored by Ali Saffaei and Farzaneh Dastan.
Connection Strength
2.705
-
Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces. Iran J Pharm Res. 2020; 19(1):1-2.
Score: 0.860
-
No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021 Apr 15; 897:173947.
Score: 0.232
-
Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. Int Immunopharmacol. 2021 Jan; 90:107205.
Score: 0.228
-
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. Int Immunopharmacol. 2020 Nov; 88:106869.
Score: 0.224
-
Extracorporeal membrane oxygenation and COVID-19: The causes of failure. J Card Surg. 2020 Oct; 35(10):2838-2843.
Score: 0.223
-
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020 Aug; 85:106688.
Score: 0.221
-
Tocilizumab administration in a refractory case of COVID-19. Int J Antimicrob Agents. 2020 Aug; 56(2):106043.
Score: 0.221
-
Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung. Iran J Allergy Asthma Immunol. 2020 May 17; 19(S1):10-12.
Score: 0.221
-
Continues renal replacement therapy (CRRT) with disposable hemoperfusion cartridge: A promising option for severe COVID-19. J Glob Antimicrob Resist. 2020 06; 21:340-341.
Score: 0.220
-
A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol. Iran J Pharm Res. 2020; 19(1):31-36.
Score: 0.054